Trade

with

Orexigen Therapeutics Inc
(NASDAQ: OREX)
AdChoices
4.08
-0.11
-2.63%
After Hours :
4.05
-0.03
-0.74%

Open

4.25

Previous Close

4.19

Volume (Avg)

2.81M (3.99M)

Day's Range

4.03-4.29

52Wk Range

3.11-7.82

Market Cap.

499.94M

Dividend Rate ( Yield )

-

Beta

2.51

Shares Outstanding

122.53M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 3.43M

    • Net Income

    • -77.67M

    • Market Cap.

    • 499.94M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -2,609.74

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.51

    • Forward P/E

    • -

    • Price/Sales

    • 126.58

    • Price/Book Value

    • 909.09

    • Price/Cash flow

    • -5.82

      • EBITDA

      • -77.04M

      • Return on Capital %

      • -74.54

      • Return on Equity %

      • -404.35

      • Return on Assets %

      • -74.54

      • Book Value/Share

      • 0.00

      • Shares Outstanding

      • 122.53M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 108.02

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 64.72

            • Pre-Tax Margin

            • -2,609.74

            • 13.77

            • Net Profit Margin

            • -2,609.74

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -17,077.50

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 149.78

              • 0.33

              • Current Ratio

              • 5.66

              • 1.52

              • Quick Ratio

              • 5.42

              • 0.87

              • Interest Coverage

              • -21.16

              • 6.77

              • Leverage Ratio

              • 257.54

              • 1.91

              • Book Value/Share

              • 0.00

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.76

                • 61.73

                • P/E Ratio 5-Year High

                • -13.33

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.46

                • 19.71

                • Price/Sales Ratio

                • 123.46

                • 3.49

                • Price/Book Value

                • 909.09

                • 3.26

                • Price/Cash Flow Ratio

                • -5.82

                • 20.88

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -404.35

                    (-94.90)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -74.54

                    (-51.60)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -82.10

                    (-75.10)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • 0.03

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -77.20M
                  Operating Margin
                  -2,251.98
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -5.82
                  Ownership

                  Institutional Ownership

                  77.72%

                  Top 10 Institutions

                  40.75%

                  Mutual Fund Ownership

                  43.94%

                  Float

                  82.16%

                  5% / Insider Ownership

                  0.29%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    8,571,509

                  • 0.00

                  • 7.00

                  • VA CollegeAmerica Small Cap World

                  •  

                    4,719,655

                  • -13.56

                  • 3.85

                  • T. Rowe Price Health Sciences Fund

                  •  

                    3,718,000

                  • 83.32

                  • 3.03

                  • SPDR® S&P Biotech ETF

                  •  

                    3,286,970

                  • 5.08

                  • 2.64

                  • Franklin Biotechnology Discovery

                  •  

                    2,506,277

                  • 21.40

                  • 2.25

                  • Vanguard Total Stock Mkt Idx

                  •  

                    2,133,366

                  • 31.14

                  • 1.74

                  • American Funds IS® Gbl Sm Cap

                  •  

                    1,964,900

                  • -3.68

                  • 1.60

                  • iShares Russell 2000 (AU)

                  •  

                    1,938,295

                  • 3.57

                  • 1.56

                  • DWS Vermögensbildungsfonds

                  •  

                    1,650,328

                  • 22.22

                  • 1.35

                  • iShares Nasdaq Biotechnology

                  •  

                    1,589,090

                  • 0.24

                  • 1.28

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    9,921,581

                  • +43.54%

                  • 8.10

                  • Capital Research Global Investors

                  •  

                    9,659,299

                  • -7.87%

                  • 7.88

                  • T. Rowe Price Associates, Inc.

                  •  

                    4,786,400

                  • +81.68%

                  • 3.91

                  • Partner Fund Management LP

                  •  

                    4,604,958

                  • -10.22%

                  • 3.76

                  • BlackRock Fund Advisors

                  •  

                    4,240,589

                  • -1.90%

                  • 3.46

                  • State Street Corp

                  •  

                    4,139,892

                  • -2.34%

                  • 3.38

                  • Franklin Advisers, Inc.

                  •  

                    3,651,477

                  • -9.35%

                  • 2.98

                  • Merrill Lynch & Co Inc

                  •  

                    3,118,748

                  • -6.44%

                  • 2.55

                  • Vanguard Group, Inc.

                  •  

                    2,992,272

                  • +1.19%

                  • 2.44

                  • First Manhattan Company

                  •  

                    2,810,055

                  • -33.25%

                  • 2.29

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Growth

                  Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are...more NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement ...morewith Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.lessless

                  Key People

                  Michael A. Narachi

                  CEO/President/Director

                  Dr. Eckard Weber,M.D.

                  Chairman of the Board/Director/Founder

                  Joseph P. Hagan

                  CFO/Chief Accounting Officer/Other Executive Officer/Treasurer

                  Patrick J. Mahaffy

                  Director

                  Brian H. Dovey

                  Director

                  • Orexigen Therapeutics Inc

                  • 3344 North Torrey Pines Court

                  • La Jolla, CA 92037

                  • USA.Map

                  • Phone: +1 858 875-8600

                  • Fax: +1 858 875-8650

                  • orexigen.com

                  Incorporated

                  2002

                  Employees

                  51

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: